Treatment of allergic asthma with monoclonal anti-IgE antibody

New England Journal of Medicine

Volumn 341, Issue 26, 1999, Pages 1966-1973

  Milgrom, Henry ^a   Fick Jr , Robert B ^b   Su, John Q ^b   Reimann, James D ^b   Bush, Robert K ^c   Watrous, Marc L ^b   Metzger, W James ^d  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b GENENTECH INC   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d EAST CAROLINA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; FLUNISOLIDE; IMMUNOGLOBULIN E ANTIBODY; MONOCLONAL ANTIBODY; PLACEBO; PREDNISOLONE; RECOMBINANT MONOCLONAL ANTIBODY E25; SALBUTAMOL; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ALLERGIC ASTHMA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; FEMALE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADOLESCENT; ADRENERGIC BETA-AGONISTS; ADULT; ANTIBODIES, MONOCLONAL; ASTHMA; CHILD; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULIN E; MALE; MIDDLE AGED; PEAK EXPIRATORY FLOW RATE; QUALITY OF LIFE;

EID: 0033599043     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199912233412603     Document Type: Article

References (36)

1. Presta L, Shields R, O'Connell L, et al. The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem 1994;269: 26368-73.
2. Shields RL, Werther WR, Zioncheck K, et al. Anti-IgE monoclonal antibodies that inhibit allergen-specific histamine release. Int Arch Allergy Immunol 1995;107:412-3.
3. Presta LG, Lahr SJ, Shields RL, et al. Humanization of an antibody directed against IgE. J Immunol 1993;151:2623-32.
4. Fox JA, Hotaling TE, Struble C, Ruppel J, Bates DJ, Schoenhoff MB. Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. J Pharmacol Exp Ther 1996;279:1000-8.
5. Fahy JV, Fleming HE, Wong HH, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997;155:1828-34.
6. Boulet LP, Chapman KR, Cote J, et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 1997;155:1835-40.
7. Demoly P, Bousquet J. Anti-IgE therapy for asthma. Am J Respir Crit Care Med 1997;155:1825-7. [Erratum, Am J Respir Crit Care Med 1997; 156:1707.]
8. National Asthma Education and Prevention Program. Guidelines for the diagnosis and management of asthma. Expert panel report 2. Clinical practice guidelines. Bethesda, Md.: National Heart, Lung, and Blood Institute, July 1997. (NIH publication no. 97-4051.)
9. Casale TB, Bernstein IL, Busse WW, et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1997;100:110-21.
10. MacGlashan DW Jr, Bochner BS, Adelman DC, et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997;158: 1438-45.
11. Nived O, Sturfelt G, Eckernas SA, Singer P. A comparison of 6 months' compliance of patients with rheumatoid arthritis treated with tenoxicam and naproxen: use of patient computer data to assess response to treatment. J Rheumatol 1994;21:1537-41.
12. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 1991;144: 1202-18.
13. Juniper EF, Guyatt GH, Ferrie PJ, Griffith LE. Measuring quality of life in asthma. Am Rev Respir Dis 1993;147:832-8.
14. Juniper EF, Guyatt GH, Feeny DH, Ferrie PJ, Griffith LE, Townsend M. Measuring quality of life in children with asthma. Qual Life Res 1996; 5:35-46.
15. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994;47:81-7.
16. Zar JH. Biostatistical analysis. 2nd ed. Englewood Cliffs, N.J.: Prentice-Hall, 1984.
17. Senn S. Statistical issues in drug development. Chichester, England: John Wiley, 1997.
18. Kaliner MA. Late phase reactions. N Engl Reg Allergy Proc 1986;7: 236-40.
19. Solley GO, Gleich GJ, Jordon RE, Schroeter AL. The late phase of the immediate wheal and flare skin reaction: its dependence upon IgE antibodies. J Clin Invest 1976;58:408-20.
20. Gleich GJ. The late phase of the immunoglobulin E-mediated reaction: a link between anaphylaxis and common allergic disease? J Allergy Clin Immunol 1982;70:160-9.
21. Laitinen LA, Heino M, Laitinen A, Kava T, Haahtela T. Damage of the airway epithelium and bronchial reactivity in patients with asthma. Am Rev Respir Dis 1985;131:599-606.
22. Lozewicz S, Gomez E, Ferguson H, Davies RJ. Inflammatory cells in the airways in mild asthma. BMJ 1988;297:1515-6.
23. Kirby JG, Hargreave FE, Gleich GJ, O'Byrne PM. Bronchoalveolar cell profiles of asthmatic and nonasthmatic subjects. Am Rev Respir Dis 1987;136:379-83.
24. Cartier A, Thomson NC, Frith PA, Roberts R, Hargreave FE. Allergen-induced increase in bronchial responsiveness to histamine: relationship to the late asthmatic response and change in airway caliber. J Allergy Clin Immunol 1982;70:170-7.
25. Galli SJ. The Paul Kallos Memorial Lecture: the mast cell: a versatile effector cell for a challenging world. Int Arch Allergy Immunol 1997;113: 14-22.
26. Sears MR, Burrows B, Flannery EM, Herbison GP, Hewitt CJ, Holdaway MD. Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. N Engl J Med 1991; 325:1067-71.
27. Warner JO, Price JF, Soothill JF, Hey EN. Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma. Lancet 1978;2:912-5.
28. Adkinson NF Jr. Immunotherapy for allergic rhinitis. N Engl J Med 1999;341:522-4.
29. Barnes PJ. Is immunotherapy of asthma worthwhile? N Engl J Med 1996;334:531-2.
30. International Asthma Management Project. International consensus report on diagnosis and treatment of asthma. Bethesda, Md.: National Heart, Lung, and Blood Institute, June 1992. (NIH publication no. 92-3091.)
31. Shields RL, Whether WR, Zioncheck K, et al. Inhibition of allergic reactions with antibodies to IgE. Int Arch Allergy Immunol 1995;107: 308-12.
32. Saban R, Haak-Frendscho M, Zine M, et al. Human FcERI-IgG and humanized anti-IgE monoclonal antibody MaE11 block passive sensitization of human and rhesus monkey lung. J Allergy Clin Immunol 1994;94: 836-43.
33. Liu J, Lester P, Builder S, Shire SJ. Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry 1995;34:10474-82.
34. Shalaby MR, Shepard HM, Presta L, et al. Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene. J Exp Med 1992;175:217-25.
35. Cacia J, Keck R, Presta LG, Frenz J. Isomerization of an aspartic acid residue in the complementarity-determining regions of a recombinant antibody to human IgE: identification and effect on binding affinity. Biochemistry 1996;35:1897-903.
36. Sullivan S, Elixhauser A, Buist AS, Luce BR, Eisenberg J, Weiss KB. National Asthma Education and Prevention Program Working Group report on the cost effectiveness of asthma care. Am J Respir Crit Care Med 1996;154:S84-S95.